Dr. Daniel Olson, MD
Claim this profileUniversity of Chicago Comprehensive Cancer Center
Studies Skin Cancer
Studies Liposarcoma
9 reported clinical trials
15 drugs studied
Area of expertise
1Skin Cancer
Stage IV
Stage III
Stage I
2Liposarcoma
Stage IV
Affiliated Hospitals
Clinical Trials Daniel Olson, MD is currently running
Immunotherapy + Chemotherapy
for Sarcoma
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting2 awards Phase 310 criteria
INBRX-106 + Pembrolizumab
for Lung Cancer
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Recruiting1 award Phase 1 & 25 criteria
More about Daniel Olson, MD
Clinical Trial Related3 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Daniel Olson, MD has experience with
- Pembrolizumab
- TAC01-HER2
- Paclitaxel
- Nivolumab
- Doxorubicin
- Pegylated Liposomal Doxorubicin Hydrochloride
Breakdown of trials Daniel Olson, MD has run
Skin Cancer
Liposarcoma
Malignant Fibrous Histiocytoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Olson, MD specialize in?
Daniel Olson, MD focuses on Skin Cancer and Liposarcoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Daniel Olson, MD currently recruiting for clinical trials?
Yes, Daniel Olson, MD is currently recruiting for 3 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Daniel Olson, MD has studied deeply?
Yes, Daniel Olson, MD has studied treatments such as Pembrolizumab, TAC01-HER2, Paclitaxel.
What is the best way to schedule an appointment with Daniel Olson, MD?
Apply for one of the trials that Daniel Olson, MD is conducting.
What is the office address of Daniel Olson, MD?
The office of Daniel Olson, MD is located at: University of Chicago Comprehensive Cancer Center, Chicago, Illinois 60637 United States. This is the address for their practice at the University of Chicago Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.